Clinical Trial Update: Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adjuvant sunitinib (Sutent) after cystectomy for high-risk urothelial carcinoma of the bladder was terminated, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: University of Michigan | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-06-28